SIGA Technologies, Inc.
660 Madison Avenue
Suite 1700
New York, NY 10065
United States
212-672-9100
http://www.siga.com
Sector: Healthcare
Industry: Biotechnology
Full Time Employees: 36
Key Executives
| Name | Title | Pay | Exercised | Age |
|---|---|---|---|---|
| Dr. Eric A. Rose M.D. | Exec. Chairman | 2.22M | N/A | 66 |
| Dr. Phillip Louis Gomez III, Ph.D. | Chief Exec. Officer & Director | 162.5k | N/A | 50 |
| Mr. Daniel J. Luckshire | CFO, Exec. VP & Sec. | 1.68M | N/A | 46 |
| Dr. Dennis E. Hruby Ph.D. | Chief Scientific Officer | 1.98M | N/A | 65 |
| Ms. Robin E. Abrams J.D. | Gen. Counsel & Chief Admin. Officer | 916.89k | N/A | 53 |
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
Description
SIGA Technologies, Inc. engages in the development and commercialization of solutions for unmet medical needs and biothreats in the United States. Its lead product is TPOXX, an orally administered antiviral drug for treating orthopoxvirus infections. SIGA Technologies, Inc. was founded in 1995 and is headquartered in New York, New York.
Corporate Governance
SIGA Technologies, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.